There are 2 versions of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (7)

Short Titles

Short Titles - House of Representatives

Short Titles as Passed House

Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019

Short Titles as Passed House for portions of this bill
  • Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
  • Over-the-Counter Monograph User Fee Act of 2019

Short Titles as Introduced

Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019

Short Titles as Introduced for portions of this bill
  • Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
  • Over-the-Counter Monograph User Fee Act of 2019

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes.


Actions Overview (2)

Date Actions Overview
01/08/2019Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 401 - 17 (Roll no. 13).(text: CR H237-262)
01/08/2019Introduced in House

All Actions (14)

Date Chamber All Actions
01/10/2019SenateRead the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 10.
01/09/2019SenateReceived in the Senate. Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
01/08/2019-7:01pmHouseMotion to reconsider laid on the table Agreed to without objection.
01/08/2019-7:01pmHouseOn motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 401 - 17 (Roll no. 13). (text: CR H237-262)
01/08/2019-6:30pmHouseConsidered as unfinished business. (consideration: CR H275-276)
01/08/2019-4:36pmHouseAt the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
01/08/2019-4:14pmHouseDEBATE - The House proceeded with forty minutes of debate on H.R. 269.
01/08/2019-4:14pmHouseConsidered under suspension of the rules. (consideration: CR H237-266)
01/08/2019-4:13pmHouseMr. Pallone moved to suspend the rules and pass the bill.
01/08/2019HouseReferred to the Committee on Energy and Commerce, and in addition to the Committees on Homeland Security, Veterans' Affairs, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
01/08/2019HouseReferred to the Committee on Energy and Commerce, and in addition to the Committees on Homeland Security, Veterans' Affairs, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
01/08/2019HouseReferred to the Committee on Energy and Commerce, and in addition to the Committees on Homeland Security, Veterans' Affairs, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
01/08/2019HouseReferred to the Committee on Energy and Commerce, and in addition to the Committees on Homeland Security, Veterans' Affairs, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
01/08/2019HouseIntroduced in House

Cosponsors (7)


Committees (4)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
House Energy and Commerce01/08/2019 Referred to
House Homeland Security01/08/2019 Referred to
House Veterans' Affairs01/08/2019 Referred to
House Judiciary01/08/2019 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Subjects (61)


Latest Summary (2)

There are 2 summaries for H.R.269. View summaries

Shown Here:
Passed House (01/08/2019)

Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019

This bill (1) reauthorizes, revises, and establishes several programs and entities relating to public-health emergency preparedness and response; and (2) addresses the approval process for over-the counter (OTC) drugs.

Among other programs, the bill reauthorizes through FY2023 and revises

  • the Public Health Emergency Preparedness cooperative-agreement program administered by the Centers for Disease Control and Prevention (CDC),
  • the Hospital Preparedness Program,
  • the CDC situational-awareness and biosurveillance program,
  • the Emergency System for Advance Registration of Volunteer Health Professionals,
  • the National Disaster Medical System,
  • the Volunteer Medical Reserve Corps,
  • the National Advisory Committee on Children and Disasters,
  • the Strategic National Stockpile, and
  • the Biomedical Advanced Research and Development Authority.

In addition, the bill provides statutory authority for existing programs, including the CDC's Children's Preparedness Unit and the Public Health Emergency Medical Countermeasures Enterprise. The bill also establishes new programs and entities, including a trauma-center grant program to support military trauma teams.

The bill further modifies the approval process for OTC drugs by providing statutory authority for the Food and Drug Administration (FDA) to (1) regulate certain OTC drugs that are marketed without an approved new-drug application, and (2) issue administrative orders specifying the conditions under which an OTC drug may be deemed safe and effective and not subject to approval as a new drug. The FDA must assess and collect user fees for OTC drugs, including OTC-drug facility and OTC-drug order-request fees.